trending Market Intelligence /marketintelligence/en/news-insights/trending/rvYXLlXaiFRKJNzKWF-3eA2 content esgSubNav
In This List

Report: Genor Biopharma to raise $200M from Hong Kong IPO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Report: Genor Biopharma to raise $200M from Hong Kong IPO

Genor BioPharma Co. Ltd. is planning to raise about $200 million from a Hong Kong IPO, Bloomberg News reported, citing people familiar with the matter.

Shanghai-based Genor BioPharma, which develops treatments for cancer, autoimmune and metabolic diseases, got in touch with potential advisers for the share sale, anonymous sources told the news outlet.

The listing of Genor BioPharma's shares under the IPO could occur in mid-2020, according to the report.

The pharmaceutical company, which is supported by private equity firm Hillhouse Capital Management Ltd., has raised about $100 million from private investors this year, Bloomberg News noted in an October article.

Genor BioPharma's valuation could reach $1 billion following the IPO, Bloomberg said, citing people familiar with the matter.